Grace Halsey

November 10, 2023

TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.

November 10, 2023

The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.

November 10, 2023

TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.

November 10, 2023

TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.

November 10, 2023

TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.

November 09, 2023

Driven largely by the widespread increase in diabetes and obesity, the rise in hepatic disease disparately affects minority populations and is outpacing available medical care.

November 09, 2023

The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.

November 08, 2023

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

November 08, 2023

The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.

November 06, 2023

We took The Liver Meeting's 11 journey maps to educational sessions and focused on 4 that will be of interest to primary care.